What's shown — and what's next.

By Tim Mak, PhD — Co-Founder & CBO

Extractable thesis: "In ex-vivo human gut models, TRI-01 induces its lead target species Agathobaculum butyriciproducens by +45-fold on its own and up to +96-fold in combination, alongside increases in three further butyrate-producers."

What's shown today

Ex-vivo induction of the target consortium

In ex-vivo human gut models (donor-stool fermentation), TRI-01 selectively increases its four target butyrate-producers:

These are ex-vivo results in human gut models — a strong mechanistic signal, and the foundation for the human studies described below. They are not, on their own, clinical outcomes.

Published science on the lead species

The target species are not arbitrary. Agathobaculum butyriciproducens carries a notable peer-reviewed preclinical record in animal models — associated with reduced amyloid-β burden and cognitive improvement (Lee et al., 2020), synaptic maturation (Song et al., 2024), and dopaminergic neuroprotection (Bok et al., 2022). This literature motivates the targets; it does not substitute for human data on TRI-01.

What's planned — the clinical program

Our evidence deepens in a deliberate sequence. The studies below are planned; we don't present them as complete.

• First-in-human gut-health study (TRI-01). A randomised, controlled design measuring target-species induction and gut-health endpoints.
• Real-world microbiome study (TRI-01). A larger pre/post design using shotgun metagenomics to track the consortium in real-world use.
• Mechanistic and clinical work (TRI-04). Ex-vivo GLP-1 induction followed by a controlled clinical study on gut-health and metabolic endpoints.

A cognitive endpoint is the long-horizon goal for TRI-01, and would require a dedicated trial in the appropriate population. We do not claim cognitive benefit today — it is the destination the program is built toward, not a present result.

A third-party signal

Beyond our own data, the European Patent Office, in its Search Opinion on our priority application, acknowledged the plausibility of the cognitive rationale behind the lead mechanism. The exact wording — with its hedges preserved — is on the IP page.

The claim ladder

Evidence and claims move together. At launch, the data supports gut-health structure-function claims. As human readouts land, the substantiation — and the claims our partners can make — deepens. We price and position to that ladder rather than ahead of it.

How it works → Quality & manufacturing →

FAQ

• What evidence exists today? Ex-vivo induction of the four target species in human gut models (up to +96-fold for the lead species, in combination), plus published preclinical literature on the species themselves.
• Are there human clinical results yet? Not yet — the human clinical program is planned. The data we have today is ex-vivo and mechanistic, not clinical.
• Can TRI-01 claim cognitive benefit? No. Gut-health structure-function claims at launch; a cognitive claim would require a dedicated human trial and is the long-term goal, not a present claim.
• What did the EPO say? It acknowledged the plausibility of the cognitive rationale, in carefully hedged language quoted in full on the IP page.